ENDURONYL
Clinical safety rating: caution
Comprehensive clinical and safety monograph for ENDURONYL (ENDURONYL).
Thiazide diuretic that inhibits the Na+-Cl− symporter in the distal convoluted tubule, reducing sodium and chloride reabsorption and promoting diuresis.
| Metabolism | Not extensively metabolized; primarily excreted unchanged in urine. |
| Excretion | Primarily renal excretion; ~50% unchanged, ~25% as deserpidine metabolites, 20% biliary-fecal. |
| Half-life | Terminal elimination half-life 10-15 hours; clinically, may require 3-5 days to reach steady state in hypertension management. |
| Protein binding | ~90% bound to plasma proteins, primarily albumin and alpha-1 acid glycoprotein. |
| Volume of Distribution | 2-4 L/kg; indicates extensive distribution into tissues, particularly adipose and brain. |
| Bioavailability | Oral: ~50% due to first-pass metabolism; parenteral not available. |
| Onset of Action | Oral: 2-4 hours for initial antihypertensive effect; parenteral not applicable. |
| Duration of Action | Oral: 12-24 hours; clinical effect persists for 24-48 hours after discontinuation due to tissue binding. |
| Molecular Weight | Methylothiazide: 360.24 Da; Deserpidine: 578.67 Da. (Combination product; for the endpoints, typical reporting would be that methylothiazide MW is 360.24 and deserpidine MW is 578.67.) |
ENDURONYL (methyclothiazide and deserpidine) is a fixed-dose combination antihypertensive. Typical adult dose: 1 tablet (methyclothiazide 5 mg / deserpidine 0.25 mg) orally once daily. Dose may be increased to 2 tablets once daily if needed.
| Dosage form | TABLET |
| Renal impairment | Contraindicated in anuria. For GFR 30-59 mL/min: use with caution, reduce dose or increase interval; monitor electrolytes. GFR <30 mL/min: not recommended. Avoid use in severe renal impairment. |
| Liver impairment | Child-Pugh A: no adjustment necessary. Child-Pugh B: use with caution; deserpidine may precipitate hepatic encephalopathy. Child-Pugh C: contraindicated due to risk of electrolyte imbalance and encephalopathy. |
| Pediatric use | Safety and efficacy not established in pediatric patients; use not recommended. |
| Geriatric use | Initiate at lowest dose: 0.5 tablet (methyclothiazide 2.5 mg / deserpidine 0.125 mg) orally once daily. Titrate slowly due to increased risk of electrolyte disturbances, hypotension, and central nervous system effects. Monitor renal function and electrolytes closely. |
| 1st trimester | Avoid: Enduronyl contains methylothiazide and deserpidine. In animal studies, thiazides have been associated with fetal harm. Deserpidine is a rauwolfia alkaloid with risk of neonatal respiratory depression, bradycardia, and hypothermia if used near term. First-trimester exposure is not recommended. |
| 2nd trimester | Avoid: Similar risks as in first trimester. Thiazides can cause electrolyte imbalances affecting fetal growth. Deserpidine may cross the placenta and cause adverse effects. |
| 3rd trimester | Avoid: Thiazides can cause neonatal thrombocytopenia, jaundice, and electrolyte disturbances. Deserpidine may cause neonatal nasal congestion, bradycardia, and hypotonia. Use near term is contraindicated. |
Clinical note
Comprehensive clinical and safety monograph for ENDURONYL (ENDURONYL).
| Placental transfer | Both methylothiazide and deserpidine cross the placenta. Thiazides are known to appear in cord blood and amniotic fluid. Deserpidine, a rauwolfia derivative, is lipophilic and readily crosses the placental barrier, achieving fetal concentrations similar to maternal levels. |
■ FDA Black Box Warning
No FDA black box warning.
| Serious Effects |
AnuriaHypersensitivity to methylothiazide, deserpidine, or other thiazides/rauwolfia alkaloidsActive peptic ulcer diseaseUlcerative colitisElectroconvulsive therapy (within 7 days)History of mental depression (especially with suicidal tendencies)
| Precautions | Hypokalemia, Hyponatremia, Hypomagnesemia, Hyperuricemia, Hyperglycemia, Hypercalcemia, Orthostatic hypotension, Photosensitivity, Systemic lupus erythematosus exacerbation, Acute angle-closure glaucoma |
| Food/Dietary | Avoid excessive intake of high-sodium foods which can reduce antihypertensive effect. Limit alcohol as it may potentiate hypotension. Grapefruit juice may increase deserpidine levels; intake should be moderate and consistent. Potassium-rich foods (bananas, oranges, leafy greens) can help counteract hypokalemia but monitor levels if on potassium supplements. |
Loading safety data…
| Breastfeeding |
| Methylothiazide is excreted in breast milk in small amounts; however, thiazides may suppress lactation. Deserpidine is excreted in breast milk and may cause adverse effects in the infant, including nasal congestion, lethargy, and bradycardia. Due to the potential for serious adverse reactions, breastfeeding is not recommended during therapy with Enduronyl. |
| Lactation Rating | L4 (Hazardous) |
| Teratogenic Risk | ENDURONYL (methyclothiazide) is a thiazide diuretic. First trimester: Limited human data; theoretical risk of teratogenicity based on animal studies showing fetal abnormalities at high doses. Second and third trimesters: May cause fetal or neonatal jaundice, thrombocytopenia, electrolyte disturbances, and possibly other adverse effects. Use only if clearly needed. |
| Fetal Monitoring | Monitor maternal blood pressure, serum electrolytes (potassium, sodium, chloride, bicarbonate), renal function, and fluid balance. Fetal monitoring includes ultrasound for growth and amniotic fluid volume due to risk of oligohydramnios. Assess for signs of neonatal jaundice and electrolyte disturbances after delivery. |
| Fertility Effects | Thiazide diuretics may cause sexual dysfunction in males and possibly anovulatory cycles in females, potentially affecting fertility. Use may mask or worsen electrolyte imbalances that impact reproductive function. Consider alternative agents if fertility is a concern. |
| Clinical Pearls | Enduronyl (methyclothiazide deserpidine) combines a thiazide diuretic with a rauwolfia alkaloid. Monitor for hypokalemia, especially in patients on digoxin. Observe for orthostatic hypotension, more common with deserpidine component. Avoid in patients with history of depressive disorders. Discontinue 2 weeks before electroconvulsive therapy. May mask signs of pheochromocytoma. |
| Patient Advice | Take medication exactly as prescribed, usually once daily in the morning to avoid nighttime urination. · Rise slowly from sitting or lying positions to prevent dizziness. · Avoid dehydration; drink adequate fluids unless instructed otherwise. · Report persistent dry mouth, drowsiness, or nasal congestion. · Do not stop suddenly; discuss with your doctor about tapering off. · Use caution when driving or operating machinery until effects are known. |